Analyst Ratings For Cellular Biomedicine Group (NASDAQ:CBMG)
Today, Cellular Biomedicine Group (NASDAQ:CBMG) stock was downgraded by Maxim Group from Buy to Hold.
Some recent analyst ratings include
- 2/1/2018-Maxim Group was Downgraded by analysts at Maxim Group from a “Buy ” rating to a ” Hold” rating.
Recent Insider Trading Activity For Cellular Biomedicine Group (NASDAQ:CBMG)
Cellular Biomedicine Group (NASDAQ:CBMG) has insider ownership of 8.20% and institutional ownership of 4.04%.
- On 12/22/2017 Andrew K. Chan, SVP, bought 8,333 with an average share price of $12.00 per share and the total transaction amounting to $99,996.00.
- On 12/22/2017 Tony Liu, CEO, bought 29,167 with an average share price of $12.00 per share and the total transaction amounting to $350,004.00.
- On 12/22/2017 Yihong Yao, Insider, bought 4,167 with an average share price of $12.00 per share and the total transaction amounting to $50,004.00.
- On 6/6/2017 Tony Liu, CEO, bought 10,000 with an average share price of $6.83 per share and the total transaction amounting to $68,300.00.
- On 2/22/2016 Andrew K Chan, SVP, sold 1,307 with an average share price of $18.22 per share and the total transaction amounting to $23,813.54.
- On 2/17/2016 Andrew K. Chan, SVP, sold 1,516 with an average share price of $17.76 per share and the total transaction amounting to $26,924.16.
- On 1/21/2016 Andrew K. Chan, SVP, sold 2,812 with an average share price of $12.90 per share and the total transaction amounting to $36,274.80.
Recent Trading Activity for Cellular Biomedicine Group (NASDAQ:CBMG)
Shares of Cellular Biomedicine Group closed the previous trading session at 19.30 down -1.45 6.99% with 18.399999618530273 shares trading hands.